6315—S (Flomoxef) in respiratory tract infections

Clinical efficacy, bacteriological effects and safety of the parenteral oxacephem antibiotic 6315-S (Flomoxef) in treatment of respiratory infections were evaluated. In 78 patients (with acute bronchitis, 1; acute exacerbation of chronic bronchitis, 6; bacterial pneumonia, 56; bronchial pneumonia, 3; secondary infection in chronic respiratory disease, 7; pulmonary suppuration, 2; and other respiratory infections, 3) 6315-S was markedly effective in 15, effective in 42, slightly effective in 13 and ineffective in 8 patients. The efficacy rate was 73.1%. Fourteen cases (e. g., mycoplasma pneumoniae) were excluded as unevaluable. As causative organisms, 30 strains were detected: S. pneumoniae, 7; S. aureus, 5; Klebsiella spp., 4; Haemophilus influenzae, 4; and 10 other strains. Of 23 strains which could be evaluated bacteriologically, 17 were eliminated by administration of 6315-S. As regards safety, out of 92 patients treated, three developed allergic symptoms, such as exanthema, and one patient gastrointestinal symptoms. Thus frequency of side-effects was 4.4% (4/92). Abnormal laboratory values were found in 17 cases (18.5%): abnormal liver fuction test, 11, eosinophilia, 4; abnormal liver function with eosinophilia, 1; prolonged prothrombin time, 1. None of these changes was serious, all values having normalized soon after cessation of treatment.